Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222990 | 1.00 | AVPR1A (0.54) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL4270284 | 0.91 | AVPR1A (0.49) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL4270941 | 0.91 | AVPR1A (0.49) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL4270943 | 0.91 | AVPR1A (0.49) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL4270282 | 0.91 | AVPR1A (0.49) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL15007392 | 0.87 | AVPR1A (0.53) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL8133200 | 0.87 | AVPR1A (0.53) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL8702090 | 0.85 | AVPR1A (0.52) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL18138952 | 0.84 | AVPR1A (0.42) | AVPR1ATNKSTNKS2KCNH2HDAC1 | |
| SCHEMBL5578848 | 0.84 | AVPR1A (0.48) | AVPR1ATNKSTNKS2KCNH2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-116113698-A | TRPML modulators | 卡斯玛治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | AVPR1A 918/4885TNKS 1486/4885TNKS2 1883/4885 |
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | AVPR1A 778/4885TNKS 2035/4885TNKS2 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.